American Well Corporation
5.32-0.02 (-0.38%)
Oct 29, 4:00:02 PM EDT · NYSE · AMWL · USD
Key Stats
Market Cap
85.93MP/E (TTM)
-Basic EPS (TTM)
-8.03Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
American Well posted Q2 revenue of $70.9M, up 13% y/y from $62.8M, fueled by $12.9M more in platform subscriptions from strategic clients, though visits dipped to $22.8M after the APC divestiture offset primary care gains. Gross margins improved sharply as costs fell 21% y/y to $31.1M, thanks to 22% headcount cuts and provider efficiencies, narrowing the operating loss to $20.4M from $52.4M. Diluted EPS of -$1.24 beat last year's -$3.36 on 15.9M shares, with no anti-dilution flagged. Cash burn eased to $29.8M YTD operating outflow, bolstered by $20.4M divestiture proceeds, leaving $219.1M in cash and no debt. The January 2025 APC sale for $20.7M upfront cash recognized $10.7M gain and shed $3.7M intangibles. Non-GAAP adjusted EBITDA not disclosed in the 10-Q. Yet competition from new digital health players lingers.
8-K
Amwell Q2 revenue rises
Amwell reported Q2 2025 revenue of $70.9 million, up from $62.8 million a year ago, with subscription revenue at $40.4 million and 1.2 million total visits. Gross margin hit 56.1%, while net loss narrowed to $19.5 million from $50.6 million; adjusted EBITDA improved to ($4.7) million from ($35.0) million. Strategic wins included adding Florida Blue and extending the US Defense Health Agency contract, validating platform value amid cost alignments. Revenue quality advances. Yet risks loom from telehealth volatility.
8-K
Annual meeting approvals secured
American Well Corporation's stockholders convened their 2025 annual meeting on June 11, approving all key proposals. They elected Stephen Schlegel, Dr. Delos Cosgrove, and Rivka Goldwasser as Class II directors until 2028, with votes ranging from 18.0 million to 18.2 million for amid 2.0 million to 2.2 million withheld. The board's choice of PricewaterhouseCoopers LLP as auditors for the year ending December 31, 2025, passed overwhelmingly at 22.8 million for, while an advisory nod to executive pay garnered 19.6 million approvals. Stockholders endorsed governance continuity.
10-Q
Q1 FY2025 results
American Well posted solid Q1 revenue growth of 12% y/y to $66.8M, fueled by a 30% jump in platform subscriptions to $32.2M from strategic clients, though visits dipped 14% y/y to $26.6M after divesting the non-core APC telepsychiatry unit in January for $20.7M upfront cash and a $10.7M gain. Operating loss narrowed sharply 59% y/y to $30.4M, thanks to 23% lower costs of revenue and deep cuts in R&D, sales, and G&A via headcount reductions and efficiency drives, while net loss improved 75% y/y to $18.4M, or $1.19 per diluted share on 15.7M shares—far better than last year's $4.94 hit. Cash burn eased to $25.1M from operating activities, leaving $222.4M in cash and equivalents with no debt. The APC sale sharpens focus on the Converge platform and profitability path. Yet competition from entrenched telehealth players like Teladoc remains a persistent drag.
8-K
Amwell Q1 revenue rises
Amwell reported Q1 2025 revenue of $66.8 million, up from $59.5 million a year ago, with subscription revenue at $32.2 million and AMG visits generating $26.6 million from 1.3 million total visits. Gross margin hit 53%, net loss narrowed to $18.4 million from $73.4 million, and adjusted EBITDA improved to ($12.2) million versus ($45.7) million last year, fueled by cost controls and a $10.7 million divestiture gain. The company reiterated 2025 guidance for $250-260 million revenue and targets cash flow breakeven in 2026. Progress accelerates, yet telehealth volatility looms.
IPO
Website
Employees
Sector
Industry
CCLD
CareCloud, Inc.
3.02-0.02
CRVW
Careview Communications, Inc.
0.03+0.00
HWAIF
HealWELL AI Inc.
1.04-0.02
OMDA
Omada Health, Inc.
25.20-1.58
OWLT
Owlet, Inc.
9.65-0.14
TDOC
Teladoc Health, Inc.
8.23-0.13
WEAV
Weave Communications, Inc.
6.58-0.42
WHTCF
Well Health Technologies Corp.
3.60-0.14
WLSS
WELSIS CORP.
3.50+0.00
WORX
SCWorx Corp.
0.30-0.02